Women in Bitcoin: This week we discuss how to protect your family
in times of financial uncertainty — consider what is surrounding us all.
In these times of financial uncertainty, financial gurus have been steadily spreading the gospel that starting a business, no matter how small, is...
Not exact matches
Important factors that could cause actual results to differ materially from those reflected
in such forward - looking statements and that should be considered
in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the
timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases
in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest
in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic
uncertainty or otherwise; 8) the effect
of economic conditions
in the industries and markets
in which we operate
in the U.S. and globally and any changes therein, including fluctuations
in foreign currency exchange rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary regulatory approvals, including our ability to obtain
in a timely fashion any required regulatory or other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both
in the U.S. and abroad; 20) the effect
of changes
in tax law, such as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction
in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over
financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco
in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations
in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
These risks and
uncertainties include, among others: the unfavorable outcome
of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any
of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA
in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components
of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence
of efficacy and adequacy
of bridging to buprenorphine; clinical development activities may not be completed on
time or at all; the results
of our clinical development activities may not be positive, or predictive
of real - world results or
of results
in subsequent clinical trials; regulatory submissions may not occur or be submitted
in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction
in payment rate or reimbursement for the company's products or an increase
in the company's
financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights
of third parties, or have unintended side effects, adverse reactions or incidents
of misuse; and those risks and
uncertainties described under the heading «Risk Factors»
in the company's most recent Annual Report on Form 10 - K and
in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
«At the same
time, there are clear downside risks: political
uncertainty, including
in Europe; the sword
of protectionism hanging over global trade; and tighter global
financial conditions that could trigger disruptive capital outflows from emerging and developing economies,» the former French finance minister said.
Such risks,
uncertainties and other factors include, without limitation: (1) the effect
of economic conditions
in the industries and markets
in which United Technologies and Rockwell Collins operate
in the U.S. and globally and any changes therein, including
financial market conditions, fluctuations
in commodity prices, interest rates and foreign currency exchange rates, levels
of end market demand
in construction and
in both the commercial and defense segments
of the aerospace industry, levels
of air travel,
financial condition
of commercial airlines, the impact
of weather conditions and natural disasters and the
financial condition
of our customers and suppliers; (2) challenges
in the development, production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or
timing of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for growth and innovation; (4) future
timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies
in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including
in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the
timing and scope
of future repurchases
of United Technologies» common stock, which may be suspended at any
time due to various factors, including market conditions and the level
of other investing activities and uses
of cash, including
in connection with the proposed acquisition
of Rockwell; (7) delays and disruption
in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes
in political conditions
in the U.S. and other countries
in which United Technologies and Rockwell Collins operate, including the effect
of changes
in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates
in the near term and beyond; (16) the effect
of changes
in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act
of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations
in the U.S. and other countries
in which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result
in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the other conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including
in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective
financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted
in their operation
of their businesses while the merger agreement is
in effect; (21) risks relating to the value
of the United Technologies» shares to be issued
in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
These risks and
uncertainties include: Gilead's ability to achieve its anticipated full year 2018
financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount
of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from
time to
time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Such risks and
uncertainties include, but are not limited to: our ability to achieve our
financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact
of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits
of such transactions, including with respect to the Merger; the substantial level
of government regulation over our business and the potential effects
of new laws or regulations or changes
in existing laws or regulations; the outcome
of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments;
uncertainties surrounding participation
in government - sponsored programs such as Medicare; the effectiveness and security
of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts
of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits
of the Merger as a condition to obtaining regulatory approvals; a longer
time than anticipated to consummate the proposed Merger; problems regarding the successful integration
of the businesses
of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion
of management's attention from ongoing business operations and opportunities during the pendency
of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability
of financing, including relating to the proposed Merger; effects on the businesses as a result
of uncertainty surrounding the proposed Merger; as well as more specific risks and
uncertainties discussed
in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section
of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section
of www.express-scripts.com.
The level
of uncertainty and volatility
in financial markets will likely remain elevated for quite some
time.
These risks and
uncertainties include food safety and food - borne illness concerns; litigation; unfavorable publicity; federal, state and local regulation
of our business including health care reform, labor and insurance costs; technology failures; failure to execute a business continuity plan following a disaster; health concerns including virus outbreaks; the intensely competitive nature
of the restaurant industry; factors impacting our ability to drive sales growth; the impact
of indebtedness we incurred
in the RARE acquisition; our plans to expand our newer brands like Bahama Breeze and Seasons 52; our ability to successfully integrate Eddie V's restaurant operations; a lack
of suitable new restaurant locations; higher - than - anticipated costs to open, close or remodel restaurants; increased advertising and marketing costs; a failure to develop and recruit effective leaders; the price and availability
of key food products and utilities; shortages or interruptions
in the delivery
of food and other products; volatility
in the market value
of derivatives; general macroeconomic factors, including unemployment and interest rates; disruptions
in the
financial markets; risk
of doing business with franchisees and vendors
in foreign markets; failure to protect our service marks or other intellectual property; a possible impairment
in the carrying value
of our goodwill or other intangible assets; a failure
of our internal controls over
financial reporting or changes
in accounting standards; and other factors and
uncertainties discussed from
time to
time in reports filed by Darden with the Securities and Exchange Commission.
It is no different this
time around except that
in the environment characterized by fear,
uncertainty, and doubt (FUD) that's prevailed since the 2008
Financial Panic, each instance
of ebbing
in data is feared to be the start
of the next economic and market meltdown.
At the
time, I wrote that «the chief effect
of Wednesday's action and accompanying statement is to once again increase
uncertainty in financial markets» (O'Driscoll 2015).
Examples
of these risks,
uncertainties and other factors include, but are not limited to the impact
of: adverse general economic and related factors, such as fluctuating or increasing levels
of unemployment, underemployment and the volatility
of fuel prices, declines
in the securities and real estate markets, and perceptions
of these conditions that decrease the level
of disposable income
of consumers or consumer confidence; adverse events impacting the security
of travel, such as terrorist acts, armed conflict and threats thereof, acts
of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments
in new markets; breaches
in data security or other disturbances to our information technology and other networks; the spread
of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes
in fuel prices and / or other cruise operating costs; any impairment
of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount
of cash to service our existing debt; restrictions
in the agreements governing our indebtedness that limit our flexibility
in operating our business; the significant portion
of our assets pledged as collateral under our existing debt agreements and the ability
of our creditors to accelerate the repayment
of our indebtedness; volatility and disruptions
in the global credit and
financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations
in foreign currency exchange rates; overcapacity
in key markets or globally; our inability to recruit or retain qualified personnel or the loss
of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays
in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases
in the price
of, or major changes or reduction
in, commercial airline services; seasonal variations
in passenger fare rates and occupancy levels at different
times of the year; our ability to keep pace with developments
in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability
of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes
in which we operate; and other factors set forth under «Risk Factors»
in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.
An exception has been made this year after the wives were nominated
in a letter noting that they have «bravely supported their husbands on the path to Christians unity:
in the process they have surrendered
financial security and family homes while having to support their families at a
time of great stress and
uncertainty.
Our Brand Is Crisis, like its documentary inspiration, understands that the key to victory
in Bolivia was reframing the election: Anyone who watched George W. Bush defeat John Kerry
in 2004 will recognize Jane's fear - mongering tactics, the way she sells Castillo's unpopular years
in office as the exact experience the country needs during a
time of uncertainty and
financial hardship.
Actual results may differ materially from those expected because
of various known and unknown risks and
uncertainties, including, but not limited to, the continuing effects
of the U.S. recession and global credit environment, other changes
in general economic and industry conditions, the award or loss
of significant client assignments,
timing of contracts, recruiting and new business solicitation efforts, currency fluctuations, and other factors affecting the
financial health
of our clients.
Since the 2008 - 09 global
financial crisis, a broad array
of risky assets, including commodities, have tended to move
in lockstep during
times of panic and heightened
uncertainty.
Even
in times of uncertainty, a disciplined saving and investing approach along with investment and tax diversification can help investors achieve their
financial goals.»
In these times of economic uncertainty, it's tempting to stuff your cash in a shoe box or mattress and forget about financial plannin
In these
times of economic
uncertainty, it's tempting to stuff your cash
in a shoe box or mattress and forget about financial plannin
in a shoe box or mattress and forget about
financial planning.
These risks include, among others, general economic conditions, local real estate conditions, tenant
financial health, the availability
of capital to finance planned growth, continued volatility and
uncertainty in the credit markets and broader
financial markets, property acquisitions and the
timing of these acquisitions, charges for property impairments, and the outcome
of legal proceedings to which the company is a party, as described
in the company's filings with the Securities and Exchange Commission.
«For equity and balanced investors, U.S. Treasury securities offer effective diversification when it's most important, during
times of extreme
financial uncertainty,» said Gastineau
in a statement.
The analyst must seek to guard himself against this danger as best he can:
in part, by dealing with those situations preferably which are not subject to sudden change;
in part, by favoring securities
in which the popular interest is keen enough to promise a fairly swift response to value elements which he is the first to recognize;
in part, by tempering his activities to the general
financial situation — laying more emphasis on the discovery
of undervalued securities when business and market conditions are on a fairly even keel, and proceeding with greater caution
in times of abnormal stress and
uncertainty.»
Such risks and
uncertainties include, among other things, the possibility that the initial public offering will not be consummated within the anticipated
time period or at all, including as the result
of regulatory, market or other factors; risks relating to Pfizer Animal Health as a standalone business as the result
of the variables and
uncertainties inherent
in business,
financial and operating performance, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; and the potential for disruption to Pfizer's Animal Health business as the result
of the initial public offering.
At a
time of financial uncertainty, self catered holidays have soared
in popularity as holidaymakers prefer the incredible value for money available when choosing a rental property over a hotel, with pureholidayhomes.com predicting that booking a self catered villa could save up to 60 % on your holiday costs when compared with a similarly classed hotel.
What was remarkable was that,
in this
time of extreme
uncertainty in financial markets, 80 per cent
of the 462 works that were offered last week were sold.
The
uncertainties in the
financial market are not caused by «climate change»
uncertainty; they are caused by political
uncertainty: «Using the excuse
of saving the planet from climate change, what insane policy, regulation, or law are these megalomaniacal politicians going to inflict upon us this
time?»
We don't want to add to your
financial stress during this
time of uncertainty in your life.
Commercial organisations becoming increasingly aware that the value
of in - house lawyers is not only
in reducing total legal spending, especially
in times of recession and
financial uncertainty, but
in accelerating business decision - making, improving management choices, and reducing risk.
Review orders should be used where there is a genuine and material
uncertainty at the
time of the original trial regarding the spouses»
financial situation
in the near future.
More generally, with respect to be both acquisitions and divestitures, by accounting for M&A activity ahead
of time in a long - term outsourcing agreement, the acquisition or sale
of an affiliate can play out through the outsourcing agreement
in a predicable manner, thereby limiting
financial and contractual
uncertainty.
During a
time of financial crisis and
uncertainty in the United States, reviewing current criminal justice policies and reforming mandatory minimums for nonviolent drug offenders is an option that Democratic and Republican lawmakers are considering.
This coverage is designed to provide
financial stability
in a
time of stress and
uncertainty, allowing you to keep your business moving forward without missing a beat.
Term insurance helps
in securing the family with
financial coverage at the
time of uncertainty or death.
Insurances has boomed
in India with increasing risk aspects, as insurance covers you from almost all
uncertainties and provides
financial support at that point
of time.
Bitcoin story is showing a path
in times of great
uncertainty when people are desperate looking out for a
financial safe haven.
Historically, during
times of war and political
uncertainty, investors tend to seek
financial safe havens
in precious metals and other long - lasting, stable investment vehicles.
Uncertainty over Brexit has caused many
of the UK's most prestigious employers to significantly cut their recruitment
of graduates, resulting
in a fall
in the number
of new graduate jobs for the first
time since the global
financial crisis.
We don't want to add to your
financial stress during this
time of uncertainty in your life.
These risks,
uncertainties and contingencies include, but are not limited to, the following: our strength and
financial condition; the
uncertainties relating to the medical needs and local economy
of Prairie du Sac, Wisconsin and the surrounding community; the strength and
financial condition
of Sauk Prairie Medical Office Building and its tenants; the
uncertainties relating to changes
in general economic and real estate conditions; the
uncertainties regarding changes
in the healthcare industry; the
uncertainties relating to the implementation
of Griffin - American Healthcare REIT IV's real estate investment strategy; and other risk factors as detailed from
time to
time in Griffin - American Healthcare REIT IV's periodic reports, as filed with the Securities and Exchange Commission.